Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

India’s economy is navigating a phase of subdued demand as growth in key sectors slows down. Multiple dynamics impact exports ...

TCS results will give an indication of what is in store for the IT sector. The strength of the US economy and the ...

TARIL is undertaking an ambitious capacity expansion program, which will not only make the company India’s largest ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

The report said "Nifty EPS is likely to grow 2 per cent (versus 4 per cent in H1FY25)-posing downgrade risks to H2FY25 consensus estimate of mid-teens growth".

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...

Media companies are likely to report a subdued performance in the upcoming Q3FY25 results, according to a report by Nuvama.